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Several defects in response to insulin have been described in vivo and in vitro in type 2 diabetes: a decreased glucose transport, defective
glucose oxidation and altered glycogen synthesis. At present, it is unknown whether glucose oxidation is primarily affected or secondarily
affected by, e.g. increased free fatty acids (FFA). The aim of this study was to evaluate whether myotubes established from type 2 diabetic
subjects express a primarily or a FFA-induced reduced insulin-mediated glucose oxidation. We have therefore investigated glucose oxidation
under basal, physiological conditions and during acute insulin stimulation with/without FFA. We found that myotubes established from type
2 diabetic subjects express a reduced insulin-stimulated increase in glucose oxidation. Moreover, an acute exposure to FFA reduces insulin-
mediated glucose oxidation without alterations in glucose uptake and glycogen synthesis. Thus, we conclude that the diminished increase in
insulin-stimulated glucose oxidation seen in type 2 diabetic subjects in vivo may be of genetic origin. Moreover, the glucose–fatty acid cycle
seems not to be crucial for the pathophysiology of insulin resistance.
D 2004 Elsevier B.V. All rights reserved.Keywords: Diabetes; Genetic; Glucose transport; Glycogen synthase; Glucose oxidation; Myotube; Skeletal muscle1. Introduction
Type 2 diabetes mellitus is characterised by impaired
insulin-mediated glucose metabolism. Several defects in
response to insulin have been described in vivo and in vitro:
a decreased glucose transport, defective glucose oxidation
and altered glycogen synthesis [1–7].
The energy required by resting healthy muscles is
obtained mainly from lipid oxidation and under conditions
of insulin-stimulated metabolism shifted to an increased
glucose oxidation due to the inhibition of lipolysis. During
exercise, fat is the most important source of energy, but also
glycogen is essential. This capacity to shift between fuels is
designated metabolic flexibility. Subjects with type 2 diabe-
tes or obesity seem to have a reduced lipid oxidation in the
basal state and a reduced capacity to shift to glucose0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: Michael.Gaster@ouh.fyns-amt.dk (M. Gaster).metabolism during insulin stimulation (metabolic inflexibil-
ity) (review Ref. [4]). In line with this, Stump et al. [8]
showed that insulin stimulation has no effect on muscle ATP
production for patients with type 2 diabetes, whereas non-
diabetic controls increased their production with 16–26%.
Recently, we have shown that lipid oxidation is primarily
reduced in myotubes from type 2 diabetic subjects with a
concomitant increase in phospholipid accumulation [9]. The
glucose oxidation rate has, however, not yet been compared
in myotubes established from controls and from subjects
with type 2 diabetes, and at present it is unknown whether
basal or insulin-mediated glucose oxidation is primarily
affected in diabetic myotubes. Furthermore, it is unknown
to which extent glucose oxidation is secondarily affected by,
e.g. increased free fatty acids (FFA). In accordance with
Randle’s glucose fatty acid cycle, an increased lipid exposure
will be followed by an increased lipid oxidation and a
reduced glucose oxidation and thereby diminish the impor-
tance of glucose oxidation. In this context, cultures of human
myotubes offer an excellent model for performing studies
under standardised conditions: First, satellite cultures
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they allow to differentiate between genetic and adaptive
processes [1,2].
In order to gain further insight into the mechanisms
underlying muscle insulin resistance, the aim of our study
was to clarify whether glucose oxidation rates were primarily
(genetically) affected in diabetic myotubes and whether acute
exposure to palmitate acid reduced glucose oxidation in
accordance with Randles glucose–fatty acid cycle (adaptive)
in myotubes established from controls and diabetic subjects.2. Methods
2.1. Materials
Dulbecco’s modified Eagle’s medium, fetal calf serum
(FCS), Ultroser G, penicillin–streptomycin–amphotericin B
and trypsin were obtained from Life Technology (Scotland,
UK). 2-[3H(G)]deoxyglucose (259.0 GBq/mmol), D-
[14C(U)]glucose (173.1 MBq/mmol), and [1-14C]palmitic
(2064.6 MBq/mmol) were purchased from Dupont, NENk
Life Science Products, Boston, MA, USA. Protein assay kit
was purchased from BioRad (Copenhagen, DK). Glycogen,
palmitic acid (PA) and ECM-gel were purchased from Sigma
Chemical Co. (St. Louis, USA). Insulin Actrapid was
obtained from Novo Nordisk (Bagsvaerd, DK).
2.2. Human study subjects
Ten obese type 2 diabetic patients and 10 matched control
subjects participated in the study (Table 1). Only sedentary
male subjects were recruited. None of the diabetic patients
had received insulin treatment. The patients had no diabetic
complications except from simplex retinopathy. The control
subjects had no family history of diabetes. All subjects gave
written informed consent, and the local ethics committee of
Funen and Vejle County approved the study.
2.3. Cell culture
Cell cultures were established as previously described
[10,11]. In brief, muscle tissue was minced, washed and
dissociated for 60 min by three treatments with 0.05%Table 1
Clinical characteristics
Control,
n= 10
Type 2
diabetic, n= 10
Age (years) 51.1F 2.0 50.4F 1.6
Body mass index (kg/m2) 29.6F 0.9 31.1F1.1
HbA1c (%) 5.1F 0.1 6.9F 0.5*
Fasting plasma glucose (mmol/l) 5.5F 0.1 10.3F 1.1*
Fasting serum insulin (pmol/l) 40F 5 69F 9*
Data represent mean (F S.E.).
*P < 0.05 for T2D compared to control.trypsin–EDTA. The harvested cells were pooled and FCS
was added as a protease inhibitor. The obtained cells were
seeded for upscaling on ECM-gel coated dishes after 30 min
of preplating. Cell cultures were established in DMEM
medium supplemented with 10% FCS, 50 U/ml penicillin,
50 Ag/ml streptomycin, 1.25 Ag/ml amphotericin B and 25
pmol/l insulin. After 24 h, cell debris and nonadherent cells
were removed by changing the growth medium to DMEM
supplemented with 2% FCS, 2% Ultroser G, 50 U/ml
penicillin, 50 Ag/ml streptomycin, 1.25 Ag/ml amphotericin
B and 25 pmol/l insulin. Cells were subcultured twice in
100-mm Petri dishes before final seeding. At 75% conflu-
ence, the growth medium was replaced by a basal medium
(DMEM medium supplemented with 2% FCS, 50 U/ml
penicillin, 50 Ag/ml streptomycin, 1.25 Ag/ml amphotericin
B and 25 pmol/l insulin) in order to induce differentiation.
The cells were cultured in humidified 5% CO2 atmosphere
at 37 jC and medium was changed every 2–3 days.3. Experimental design
Human myotubes established from controls and subjects
with type 2 diabetes were allowed to differentiate under
physiological conditions of insulin (25 pmol/l) and glucose
(5.5 mmol/l) for 8 days. All myotube cultures were used for
analysis day 8 after onset of differentiation. Myotubes were
rinsed twice and incubated for 4 h with either glucose or
glucose supplemented with 0.6 mmol/l palmitate acids. The
doses and the accumulation time were selected in accor-
dance with our previous study evaluating palmitate oxida-
tion [9]. Corresponding values of glucose uptake, glucose
oxidation and glycogen synthesis were determined as de-
scribed in Analysis at an insulin concentration of 25 pmol/
l (designated baseline) and during acute insulin stimulation
(1 Amol/l).4. Analysis
4.1. Glucose oxidation
Cells were cultured in 12.5-cm2 flasks and differentiated
as described above. Cultures were exposed to DMEM
supplemented with 0.24 mmol/l fatty free albumin, 50 U/
ml penicillin, 50 Ag/ml streptomycin, 1.25 Ag/ml amphoter-
icin B, D-[14C(U)]glucose (2.0 ACi/ml) and 25 pmol/l or 1
Amol/l insulin, respectively, in order to study basal and
insulin-mediated glucose oxidation. To study the impact of
acute exposure to palmitate, sister cultures were incubated
under the abovementioned conditions supplemented with 0.6
mmol/l palmitate. Flasks were air-tightened with a rubber
stopper. After 4 h, 300-Al phenyl ethylamine–methanol (1:1,
v/v) was added with a syringe to a centre well containing a
folded filter paper. Subsequently, 300-Al 1 M perchloric acid
was added to the cells through the stopper tops by means of a
Fig. 1. Effect of insulin and/or palmitate acids on glucose oxidation in
myotubes established from controls and type 2 diabetic subjects. Fully
differentiated myotubes were acutely exposed to insulin (1 Amol/l) and/or
palmitate acids (0.6 mmol/l) for 4 h. (a) Basal conditions (open bars), insulin-
stimulated conditions (hatched bars). Data are means+S.E.; n=10 subjects in
each group. (b) The absolute differences between the basal and the insulin-
stimulated glucose oxidation (DGox) in control (open bars) and diabetic cultures
(black bars). Results are shown asmeansF S.E., n=10 subjects in each group.
*P<0.05 vs. corresponding basal condition or as indicated by bars. C= control,
DM= type 2 diabetes, PA= exposure to palmitate acids.
M. Gaster, H. Beck-Nielsen / Biochimica etsyringe. The flasks were placed for a minimum of 1 h at room
temperature to trap labelled CO2. Cell-free flasks (no cell
controls) went through the same procedure to correct for
unspecific CO2 trapping.
4.2. Glycogen synthesis
Cells were grown and differentiated in 12-well plates as
described above. Cultures were exposed to DMEM supple-
mented with 0.24 mmol/l fatty free albumin, 50 U/ml
penicillin, 50 Ag/ml streptomycin, 1.25 Ag/ml amphotericin
B, D-[14C(U)]glucose (1.0 ACi/well) and 25 pmol/l or 1
Amol/l insulin, respectively in order to study basal and
insulin-mediated glucose uptake. To study the impact of
acute exposure to palmitate, sister cultures were incubated
under the abovementioned conditions supplemented with 0.6
mmol/l palmitate. The reaction was stopped after 4 h by
aspirating the reaction mixture and rapidly rinsing each well
four times with PBS at 4 jC. Measurement of glycogen
synthesis using this method is linear up to 6 h (data not
shown). Cells were solubilised by adding 0.5-ml 1.0 M KOH
and afterwards heated at 70 jC for 20 min. To the sample
was added 100-Al saturated Na2SO4, 100-Al 25 mg/ml
glycogen in distilled water (freshly made) and 9-ml ice-cold
absolute ethanol, and then left at  70 jC for 48 h for
glycogen precipitation. The tubes were centrifuged
(2000 g, 20 min, 4 jC) and the supernatant immediately
removed and discarded. The glycogen precipitate was redis-
solved in 500-Al distilled water by heating at 70 jC for 10
min, 9-ml ice-cold absolute ethanol was added and then left
at  20 jC for a minimum of 24 h. Again, the tubes were
centrifuged, the supernatants removed and 500-Al distilled
water was added and the glycogen dissolved. Five-hundred
microliters was removed for scintillation counting [12].
4.3. Glucose uptake
Cells were grown and differentiated in 12-well plates as
described above. Cultures were exposed to DMEM supple-
mented with 0.24 mmol/l fatty free albumin, 50 U/ml peni-
cillin, 50 Ag/ml streptomycin, 1.25 Ag/ml amphotericin B, 2-
[3H]deoxyglucose (0.2 ACi/well) and 25 pmol/l or 1 Amol/
l insulin, respectively, in order to study basal and insulin-
mediated glucose uptake. To study the impact of acute
exposure to palmitate, sister cultures were incubated under
the above mentioned conditions supplemented with 0.6
mmol/l palmitate. The reaction was stopped after 4 h by
aspirating the reaction mixture and rapidly rinsing each well
four times with PBS at 4 jC. Measurement of glucose uptake
using this method is linear up to 6 h (data not shown). Cells
were solubilised by adding 0.5-ml 0.1 M NaOH. An aliquot
of 50 Al was removed for protein determination. The remain-
ing fluid was placed in a scintillation vial, and scintillation
fluid was added. Glucose transport activity is expressed as
moles of 2-deoxy-glucose taken up per minute per milligram
of total protein.4.4. Statistical analysis
Data in text, tables and figures are given as meanF S.E.
Statistical analyses were performed using INSTAT 2.01
(GraphPad, USA). Students’ t-test was used for unpaired
and paired t-test for paired comparisons. PV 0.05 was con-
sidered significant.
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5.1. Insulin-mediated glucose oxidation is reduced in
diabetic myotubes (Fig. 1)
We determined the baseline and insulin-stimulated glu-
cose oxidation rates in myotubes established from type 2
diabetic and control subjects at 5.5 mmol/l glucose. Baseline
glucose oxidation showed no significant difference between
diabetic and control myotubes (382F 42 vs. 429F 41 pmol/
mg/min, P>0.59) (Fig. 1a). Glucose oxidation was sensitive
to insulin stimulation in myotubes established from controls
Fig. 3. Effect of insulin and/or palmitate acids on glucose uptake in
myotubes established from controls and type 2 diabetic subjects. Fully
differentiated myotubes were acutely exposed to insulin (1 Amol/l) and/or
palmitate acids (0.6 mmol/l) for 4 h. Basal conditions (open bars), insulin-
stimulated conditions (hatched bars). Data are means + S.E.; n= 10 subjects
in each group. *P < 0.05 vs. corresponding basal condition or as indicated
by bars. C = control, DM= type 2 diabetes, PA= exposure to palmitate
acids.
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myotubes established from subjects with type 2 diabetes
(423F 38 vs. 429F 41 pmol/mg/min, P> 0.54). Insulin-
stimulated glucose oxidation was significantly higher in
control myotubes compared to diabetic myotubes (531F 46
vs. 423F 38 pmol/mg/min, P < 0.05). In order to gain further
insight into the differences between diabetic and control
myotubes during acute insulin stimulation, we compared the
absolute differences between the basal and the insulin-stimu-
lated states (DGox). The DGox for acute insulin stimulation
was significantly higher in the control myotubes compared
to myotubes established from type 2 diabetic subjects (114
F 37 vs. 5F 19 pmol/mg/min, P< 0.004) (Fig. 1b).
5.2. Insulin-stimulated glycogen synthesis was reduced in
diabetic myotubes (Fig. 2)
The glycogen synthesis rate in myotubes established
from diabetic and control subjects on day 8 is shown in
Fig. 2. No significant difference of baseline glycogen
synthesis was found between diabetic and control myotubes
(68F 12 vs. 50F 8 pmol/mg/min, P>0.05). The glycogen
synthesis rate during acute insulin stimulation was signifi-
cantly lower in diabetic myotubes compared to control
myotubes (141F 22 vs. 87F 12 pmol/mg/min, P < 0.02).
However, acute insulin stimulation significantly increases
the glycogen synthesis rate in both control (141F 22 vs.
68F 12 pmol/mg/min, P < 0.01) and diabetic myotubes
(87F 12 vs. 50F 8 pmol/mg/min, P < 0.05) (Fig. 2).
5.3. Glucose uptake was insulin sensitive but with no
differences between groups (Fig. 3)
We determined the glucose uptake at a glucose concen-
tration of 5.5 mmol/l in control and diabetic myotubes. NoFig. 2. Effect of insulin and/or palmitate acids on glycogen synthesis in
myotubes established from controls and type 2 diabetic subjects. Fully
differentiated myotubes were acutely exposed to insulin (1 Amol/l) and/or
palmitate acids (0.6 mmol/l) for 4 h. Basal conditions (open bars), insulin-
stimulated conditions (hatched bars). Data are means + S.E.; n= 10 subjects
in each group. *P < 0.05 vs. corresponding basal condition or as indicated by
bars. C = control, DM= type 2 diabetes, PA= exposure to palmitate acids.significant difference of baseline (2.37F 0.08 vs. 2.12F
0.15 nmol/min/mg, P> 0.32) or insulin-mediated (2.85
F 0.14 vs. 2.52F 0.16 nmol/min/mg, P> 0.32) glucose
uptake was found between diabetic and control myotubes
(Fig. 3). Control myotubes (2.85F 0.14 vs. 2.37F 0.08
nmol/min/mg, P < 0.02) and myotubes established from
type 2 diabetic subjects (2.52F 0.16 vs. 2.12F 0.15
nmol/min/mg, P < 0.01) were sensitive to insulin stimula-
tion (Fig. 3).
5.4. Impact of acute lipid exposure
In an attempt to evaluate the effect of acute lipid
exposure on glucose metabolism in myotubes established
from controls and type 2 diabetic subjects, we determined
glucose oxidation, glucose transport, and glycogen synthesis
in sister cultures under the above mentioned conditions
supplemented with 0.6 mmol/l palmitate.
5.5. Acute lipid exposure decreases insulin-mediated
glucose oxidation in control myotubes (Fig. 1)
Baseline glucose oxidation was significantly reduced
when diabetic myotubes was exposed to palmitate
(P < 0.05). In contrast, control myotubes expressed no
significant changes in baseline glucose oxidation when
exposed to palmitate (P> 0.05) (Fig. 1). Acute lipid
exposure decreases insulin-mediated glucose oxidation in
control myotubes (P < 0.05) (Fig. 1), but not in diabetic
myotubes (P= 0.06). DGox for acute insulin stimulation
was reduced when exposed to palmitate in control myo-
tubes (114F 37 vs. 8F 13 pmol/mg/min, P < 0.05), but
not in diabetic myotubes (5F 19 vs. 22F 20 pmol/mg/
min, P>0.8).
ica et Biophysica Acta 1690 (2004) 85–91 895.6. Glycogen synthesis in diabetic myotubes and control
myotubeswas not affected by acute palmitate exposure (Fig. 2)
Baseline and insulin-stimulated glycogen synthesis were
not affected by acute exposure to palmitate acid in control
(P>0.05) and type 2 diabetic myotubes (P>0.05) (Fig. 2).
5.7. Acute palmitate exposure and glucose uptake (Fig. 3)
Baseline glucose uptake in control myotubes, but not in
diabetic myotubes, expressed a significant increase in glu-
cose uptake (P < 0.05) under acute lipid exposure. Insulin-
stimulated glucose uptake was not hampered by acute lipid
exposure neither in control (P < 0.05) nor in diabetic myo-
tubes (P < 0.05). Insulin-stimulated glucose uptake was not
significantly different between diabetic and control myotubes
(P>0.60).
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The present study demonstrates that diabetic myotubes
express a reduced insulin-mediated glucose oxidation and
that acute FFA exposure hampers the insulin-mediated in-
crease in glucose oxidation in control myotubes, but without
reducing glucose uptake and glycogen synthesis. Thus, the
diminished increase in insulin-stimulated glucose oxidation
seen in type 2 diabetic subjects in vivo may be of genetic
origin. Furthermore, the glucose–fatty acid cycle seems not
to be crucial to the pathophysiology of insulin resistance.
Previously, it has been described that subjects with type 2
diabetes seem to possess an increased basal glucose oxida-
tion and a reduced capacity to increase glucose oxidation
during insulin stimulation (review Ref. [4]), but the mech-
anism responsible for this has not yet been identified.
Whether the observed changes represent adaptive compen-
sation at the cellular level or the direct expression of a
primary genetic trait remains uncertain. In this context,
cultures of human myotubes offer excellent material for
performing studies under standardised conditions. The un-
derlying idea when using myotubes is that myotubes only
express their genetic background when precultured under
physiological conditions and their adaptive traits when
precultured under ‘‘inducing conditions’’. A genetic deter-
mination of known in vivo pathophysiological abnormalities
will be evident if the abnormality is present in vitro under
physiological conditions. Our study showed that the base-
line glucose oxidation remained unchanged and insulin-
stimulated glucose oxidation was significantly reduced in
myotubes established from type 2 diabetic subjects com-
pared to myotubes established from control subjects. This
suggests that the increased basal glucose oxidation in
diabetic subjects in vivo is an adaptive reaction, whereas
the reduced glucose oxidation during insulin stimulation
(review Ref. [4]) in diabetic subjects is of genetic origin.
The inducing mechanisms responsible for this increasedbasal glucose oxidation in diabetic subjects are at present
unclear.
Our observation of an impairment of insulin-stimulated
glucose oxidation in diabetic myotubes is in line with the
very recent work from Stump et al. [8] showing that insulin
stimulation has no effect on muscle ATP production in
patients with type 2 diabetes, whereas non-diabetic control
subjects increased their production with 16–26%. Based on
our findings, this reduced capacity to increase ATP produc-
tion in type 2 diabetes seems to be a primary defect.
Moreover, our study shows that the reduced insulin-medi-
ated glucose oxidation is based neither on a concomitant
reduced glucose uptake nor on an increased lipid oxidation
[9]. Several studies have described a reduced expression of
oxidative enzymes and activity [13–15] and, recently, Kelly
et al. [16] described that both obese and diabetic subjects
express mitochondrial dysfunction. In our study, myotubes
were established from obese and obese with type 2 diabetes.
Therefore, obesity per se or mitochondrial dysfunction due
to obesity cannot explain all our findings. Moreover, both an
affection of lipid oxidation [9] and insulin-mediated glucose
oxidation without affection of baseline glucose oxidation
imply that these oxidative defects in diabetic myotubes
cannot be explained by a simple reduction in mitochondrial
number or function.
The key regulator of glucose oxidation is pyruvate de-
hydrogenase (PDH), which is sensitive to insulin stimulation
[17]. PDH activity is regulated by insulin-sensitive PDH
phosphatase (activating PDH) and PDH kinase (inactivating)
(PDK), which can be activated allosterically by acetyl-CoA,
NADH and ATP. Mammalian tissues express four PDK
isoenzymes [18] and two pyruvate dehydrogenase phos-
phatase isoenzymes [19]. Especially PDK4 has been
interesting as the expression and activity are increased
in rats with streptozotocin-induced diabetes which is not
completely restored back to the level of control rats
during insulin stimulation [20]. It could be speculated
that the PDK4 activity is increased in diabetic myotubes
either as increased expression or increased allosteric
activation, thereby reducing glucose oxidation in diabetic
myotubes. However, further studies are needed to test
whether this hypothesis could explain primarily reduced
insulin-mediated glucose oxidation in diabetic myotubes/
subjects.
The well-described defect in the pathophysiology of type
2 diabetes is reduced insulin-mediated glycogen synthesis in
skeletal muscles [1,2,7]. In line with previous studies, we
showed that insulin-stimulated glycogen synthesis is re-
duced in diabetic myotubes compared to control myotubes,
hence confirming that insulin-stimulated glycogen synthesis
seems primarily affected in muscular insulin resistance. The
observation that insulin-mediated glycogen synthesis and
glucose oxidation are primarily affected emphasises that the
impact of diabetes could be limited to the insulin effect.
However, we recently showed that palmitate oxidation in
diabetic myotubes seems primarily affected under baseline
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rather be seen as a changed metabolic setting.
The following question arises: why is glucose taken up
and not stored as glycogen or oxidised to the same extent in
diabetic myotubes as seen in control myotubes? This may be
explained by the following: The MIRKO mouse, with
muscle specific inactivation of the insulin receptor gene
[21], expresses a reduced insulin-stimulated glucose trans-
port and glycogen synthesis with a concomitant threefold
increase in insulin-stimulated glucose transport in adipose
tissue, thus indicating that selective muscular insulin resis-
tance redistributes glucose to adipose tissue [22]. In accor-
dance with the MIRKO mice, it could be speculated that
these primary defects in myotubes established from type 2
diabetic subjects are responsible for the redistribution of
glucose to other tissues, e.g. adipose tissue. This redistribu-
tion may add to the development of obesity as seen in the
MIRKO mouse.
Previous studies have shown that the capacity to take up
glucose under basal conditions and during acute insulin
stimulation is reduced in diabetic myotubes [3,23], but the
insulin responsiveness is conserved [1,3,23]. No difference
was found in glucose uptake in myotubes established from
insulin-resistant and insulin-sensitive first-degree relatives
[24]. In line with this, the present study confirms a con-
served insulin responsiveness in diabetic myotubes, increas-
ing the evidence that the glucose transport does not seem to
be primarily insulin-resistant in diabetic myotubes. In hu-
man skeletal muscles, most of the glucose taken up and
mediated by insulin is stored as glycogen [25]. In contrast,
only 9–16% of insulin-mediated glucose uptake in myo-
tubes is stored as glycogen, thus implying that even when
glycogen is primarily affected it would be impossible to
detect an impact on glucose uptake. However, the identical
glucose uptake flux ensures that the described primary
defects in glucose oxidation and glycogen synthesis are
not based on differences in glucose uptake.
Several in vivo studies have found that increased palmi-
tate exposure is followed by an increased lipid oxidation and
a reduced glucose oxidation, but glucose disposal was only
reduced after former pathways had been affected, thus
indicating that Randle’s cyclus is functionally operating,
but not responsible for insulin resistance [26,27]. In line
with this, we showed that acute palmitate exposure was
followed by a hampered insulin-mediated glucose oxidation
in control myotubes, but not in glucose uptake or storage.
By choosing a 4-h exposure at a 0.6 mmol/l palmitate
concentration, we separated the palmitate effects on glucose
oxidation from those on glucose transport and glycogen
synthesis, thus allowing us to study the effect of palmitate
on glucose oxidation. Although neither reduced glucose
transport nor glycogen synthesis was detected in our cul-
tured myotubes exposed to palmitate, several studies have
shown that glucose transport and glycogen synthesis are
reduced when the cells are exposed to increasing levels of
FFA for longer periods of time [28,29]. The finding thatacute palmitate exposure hampered the insulin-mediated
increase in glucose oxidation in control myotubes may
ensure that, under conditions of active lipolysis, glucose is
not oxidised in muscles. The responsible mechanism may be
the increasing palmitate level rising the acetyl-CoA level
and thereby allosteric inhibiting PDH. We studied the effect
of a specific fatty acid, palmitate, but other fatty acids
(unsaturated or essential fatty acids) may have other effects
on the metabolism than secondary insulin resistance on
glucose oxidation.
In conclusion, our data suggest that myotubes established
from type 2 diabetic subjects express an inborn reduced
insulin-mediated glucose oxidation and glycogen synthe-
sis—both may be a part of insulin resistance in type 2
diabetes. Furthermore, acute exposure to palmitate induced
insulin resistance at the glucose oxidation level. Although
acute exposure to palmitate reduced glucose oxidation,
glucose transport was not reduced, thus suggesting that
Randle’s cyclus is not a part of the pathogenesis of insulin
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